These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30408079)

  • 61. Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening.
    Sarpel D; Baichoo E; Dieterich DT
    Expert Rev Anti Infect Ther; 2016; 14(5):511-21. PubMed ID: 27043049
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.
    Sweeney S; Ward Z; Platt L; Guinness L; Hickman M; Hope V; Maher L; Iversen J; Hutchinson SJ; Smith J; Ayres R; Hainey I; Vickerman P
    Addiction; 2019 Mar; 114(3):560-570. PubMed ID: 30674091
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
    Hahné SJ; Veldhuijzen IK; Wiessing L; Lim TA; Salminen M; Laar Mv
    BMC Infect Dis; 2013 Apr; 13():181. PubMed ID: 23597411
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors.
    Day FL; Karnon J; Rischin D
    J Clin Oncol; 2011 Aug; 29(24):3270-7. PubMed ID: 21788556
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
    Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
    Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
    Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
    J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049.
    Xu X; Wu C; Jiang L; Peng C; Pan L; Zhang X; Shen W; Chen L; Lou Z; Xu K; Li L; Dong Y; Ruan B
    Int J Health Policy Manag; 2022 Oct; 11(10):2115-2123. PubMed ID: 34664496
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey.
    Papatheodoridis G; Sypsa V; Kantzanou M; Nikolakopoulos I; Hatzakis A
    J Viral Hepat; 2015 Apr; 22(4):409-15. PubMed ID: 25209157
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
    Mafirakureva N; Lim AG; Khalid GG; Aslam K; Campbell L; Zahid H; Van den Bergh R; Falq G; Fortas C; Wailly Y; Auat R; Donchuk D; Loarec A; Coast J; Vickerman P; Walker JG
    J Viral Hepat; 2021 Feb; 28(2):268-278. PubMed ID: 33051950
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
    Chhatwal J; Kanwal F; Roberts MS; Dunn MA
    Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
    Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses.
    Mattingly TJ; Love BL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):879-886. PubMed ID: 32584675
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis.
    Requena-Méndez A; Bussion S; Aldasoro E; Jackson Y; Angheben A; Moore D; Pinazo MJ; Gascón J; Muñoz J; Sicuri E
    Lancet Glob Health; 2017 Apr; 5(4):e439-e447. PubMed ID: 28256340
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
    Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
    Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
    Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
    Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial.
    Flanagan S; Kunkel J; Appleby V; Eldridge SE; Ismail S; Moreea S; Griffiths C; Walton R; Pitt M; Salmon A; Madurasinghe V; Barnes E; Simms E; Agarwal K; Foster GR
    Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):32-44. PubMed ID: 30477810
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.
    Marco A; Domínguez-Hernández R; Casado MA
    Rev Esp Sanid Penit; 2020; 22(2):66-74. PubMed ID: 32697276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.